Targeting Serine in Cancer: Is Two Better Than One?

Aitziber Buqué; Lorenzo Galluzzi; David C. Montrose

doi:10.1016/j.trecan.2021.06.004

Targeting Serine in Cancer: Is Two Better Than One?

Aitziber Buqué
, Lorenzo Galluzzi
, David C. Montrose

Cornell University
Weill Cornell Medical College
Stony Brook University

Research output: Contribution to journal › Short survey › peer-review

28 Scopus citations

Abstract

Several recent preclinical studies have demonstrated that simultaneously blocking exogenous and endogenous sources of serine in malignant cells mediates superior anticancer effects as compared with limiting either source alone. Here, we critically summarize key developments in targeting serine to treat cancer and discuss persisting challenges for implementing such a therapeutic approach in patients.

Original language	English
Pages (from-to)	668-670
Number of pages	3
Journal	Trends in Cancer
Volume	7
Issue number	8
DOIs	https://doi.org/10.1016/j.trecan.2021.06.004
State	Published - Aug 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

DNA damage
PHGDH
PSAT1
PSPH
colorectal cancer
glycine

Access to Document

10.1016/j.trecan.2021.06.004

Cite this

@article{00f3913817eb477482328e8ccdb23cb4,

title = "Targeting Serine in Cancer: Is Two Better Than One?",

abstract = "Several recent preclinical studies have demonstrated that simultaneously blocking exogenous and endogenous sources of serine in malignant cells mediates superior anticancer effects as compared with limiting either source alone. Here, we critically summarize key developments in targeting serine to treat cancer and discuss persisting challenges for implementing such a therapeutic approach in patients.",

keywords = "DNA damage, PHGDH, PSAT1, PSPH, colorectal cancer, glycine",

author = "Aitziber Buqu{\'e} and Lorenzo Galluzzi and Montrose, \{David C.\}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = aug,

doi = "10.1016/j.trecan.2021.06.004",

language = "English",

volume = "7",

pages = "668--670",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "8",

}

TY - JOUR

T1 - Targeting Serine in Cancer

T2 - Is Two Better Than One?

AU - Buqué, Aitziber

AU - Galluzzi, Lorenzo

AU - Montrose, David C.

PY - 2021/8

Y1 - 2021/8

N2 - Several recent preclinical studies have demonstrated that simultaneously blocking exogenous and endogenous sources of serine in malignant cells mediates superior anticancer effects as compared with limiting either source alone. Here, we critically summarize key developments in targeting serine to treat cancer and discuss persisting challenges for implementing such a therapeutic approach in patients.

AB - Several recent preclinical studies have demonstrated that simultaneously blocking exogenous and endogenous sources of serine in malignant cells mediates superior anticancer effects as compared with limiting either source alone. Here, we critically summarize key developments in targeting serine to treat cancer and discuss persisting challenges for implementing such a therapeutic approach in patients.

KW - DNA damage

KW - PHGDH

KW - PSAT1

KW - PSPH

KW - colorectal cancer

KW - glycine

UR - https://www.scopus.com/pages/publications/85109488761

U2 - 10.1016/j.trecan.2021.06.004

DO - 10.1016/j.trecan.2021.06.004

M3 - Short survey

C2 - 34219053

AN - SCOPUS:85109488761

SN - 2405-8033

VL - 7

SP - 668

EP - 670

JO - Trends in Cancer

JF - Trends in Cancer

IS - 8

ER -

Targeting Serine in Cancer: Is Two Better Than One?

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this